Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 19/20 | 0.76 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.64 |
| ▸ | CDK1 | P06493 | 1/20 | 0.64 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.64 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.64 |
| ▸ | IGF1R | P08069 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12606356 | 0.87 | RIPK1 (0.70) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL31064964 | 0.86 | RIPK1 (1.00) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL6286704 | 0.78 | RIPK1 (0.69) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL1778522 | 0.78 | RIPK1 (1.00) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL31710670 | 0.78 | RIPK1 (0.61) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL31064954 | 0.78 | RIPK1 (1.00) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL5716685 | 0.78 | RIPK1 (0.68) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL27889519 | 0.77 | CCNB2 (0.68) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL22291215 | 0.77 | AMY1A (0.54) | RIPK1 | |
| SCHEMBL11531018 | 0.77 | MAPT (0.60) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859581-B2 | Azaheterocyclic compounds as kinase inhibitors | MERCK PATENT GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| EP-1874769-B1 | NOVEL AZA- HETEROCYCLES SERVING AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-09-14 | — | — | EP | disclosed |
| US-20080176892-A1 | Anticancer agents; synergistic use; regulate and/or modulate tyrosine kinase signal transduction particularly an IGF-R1-inhibiting action; 3-[2-(3,4,5-trimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-4-ylamino]benzonitrile; reaction with arylsilylacetylene | MERCK PATENT GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176892-A1 | Anticancer agents; synergistic use; regulate and/or modulate tyrosine kinase signal transduction particularly an IGF-R1-inhibiting action; 3-[2-(3,4,5-trimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-4-ylamino]benzonitrile; reaction with arylsilylacetylene | IGF1R, IGFBP1, ERBB2 | RIPK1 598/4885CCNB2 693/4885CDK1 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.